참고문헌
- Andreassen PR, Lacroix FB, Villa-Moruzzi E, et al (1998). Differential subcellular localization of protein phosphatase-1 alpha, gamma1, and delta isoforms during both interphase and mitosis in mammalian cells. J Cell Biol, 141, 1207-15. https://doi.org/10.1083/jcb.141.5.1207
- Booher R, Beach D (1989). Involvement of a type 1 protein phosphatase encoded by bws1+ in fission yeast mitotic control. Cell, 57, 1009-16. https://doi.org/10.1016/0092-8674(89)90339-5
- Ceulemans H, Bollen M (2004). Functional diversity of protein phosphatas-1, a cellular economizer and reset button. Physiol Rev, 84, 1-39. https://doi.org/10.1152/physrev.00013.2003
-
Cheng A, Dean NM, Honkanen RE (2000). Serine/Threonine protein phosphatase type
$1{\gamma}1$ is required for the completion of cytokinesis in human A549 lung carcinoma cells. J Biol Chem, 275, 1846-54. https://doi.org/10.1074/jbc.275.3.1846 - Choi YH, Yoo YH (2012). Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep, 28, 2163-9.
- Chun E, Lee KY (2004). Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem. Biophys. Res Commun, 315, 771-9.
- Cohen PT (2002). Protein phosphatase 1-targeted in many directions. J Cell Sci, 115, 241-56.
- Das KC, White CW (1997). Activation of NF-kB by antineoplastic agents. Role of protein kinase C. J Biol Chem, 272, 14914-20. https://doi.org/10.1074/jbc.272.23.14914
- Horwitz SB (1992). Mechanism of action of taxol. Trends Pharmacol Sci, 13, 134-6. https://doi.org/10.1016/0165-6147(92)90048-B
- Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
- Jordan MA, Wendell K, Gardiner S, et al (1996). Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res, 56, 816-25.
- Ke QH, Zhou SQ, Du W, et al (2012). Early efficacy of taxotere and cisplatin chemo-radiotherapy. Asian Pac J Cancer Prev, 13, 617-9 https://doi.org/10.7314/APJCP.2012.13.2.617
- Kinoshita N, Ohkura H, Yanagida M (1990). Distinct, essential roles of type 1 and 2A protein phosphatases in the control of the fission yeast cell division cycle. Cell, 63, 405-15. https://doi.org/10.1016/0092-8674(90)90173-C
- Koshiyama M, Kinezaki M, Uchida T, et al (2006). Chemosensitivity testing of paclitaxel versus docetaxel in human gynecological carcinomas: a comparison with carboplatin. Anticancer Res. 26, 3655-9.
-
Lee M, Jeon YJ (2001). Paclitaxel-induced immune suppression is associated with NF-
${\kappa}B$ activation via conventional PKC isotypes in lipopolysaccharide-stimulated 70Z/3 pre-B lymphocyte tumor cells. Mol Pharmacol, 59, 248-53. - Long HJIII (2007). Management of metastatic cervical cancer: review of the literature. J Clin Oncol, 25, 2966-74. https://doi.org/10.1200/JCO.2006.09.3781
- Mabuchi S, Ohmichi M, Kimura A, et al (2002). Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem, 277, 33490-500. https://doi.org/10.1074/jbc.M204042200
- Nguyen DM, Chen GA, Reddy R, et al (2004). Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg, 127, 365-75. https://doi.org/10.1016/j.jtcvs.2003.09.033
- Nimmo GA, Cohen P (1978). The regulation of glycogen metabolism. Purification and characterisation of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Eur J Biochem, 87, 341-51. https://doi.org/10.1111/j.1432-1033.1978.tb12383.x
- Ozes ON, Mayo LD, Gustin JA, et al (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serinethreonine kinase. Nature, 401, 82-5. https://doi.org/10.1038/43466
- Page C, Lin H J, Jin Y, et al (2000). Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res, 20, 407-16.
- Pahl HL (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-66. https://doi.org/10.1038/sj.onc.1203239
- Paulson JR, Patzlaff JS, Vallis AJ (1996). Evidence that the endogenous histone H1 phosphatase in HeLa mitotic chromosomes is protein phosphatase 1, not protein phosphatase 2A. J Cell Sci, 109, 1437-47.
- Pianetti S, Arsura M, Romieu-Mourez R, et al (2001). Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/ Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene, 20, 1287-99. https://doi.org/10.1038/sj.onc.1204257
- Sakoff JA, Ackland SP, Baldwin ML, et al (2002). Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest New Drugs, 20, 1-11. https://doi.org/10.1023/A:1014460818734
-
Smitha VB, Vineshkumar TP, Ayswaria D, et al (2005). Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-
${\kappa}B$ and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem, 280, 6301-8. https://doi.org/10.1074/jbc.M410647200 - Sogawa K, Yamada T, Sugita A, et al (1996). Role of protein phosphatase in malignant osteogenic and soft tissue tumors. Res Commun Mol Pathol Pharmacol, 93, 33-42.
- Sparano JA, Wang M, Martino S, et al (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl J Med, 358, 1663-71. https://doi.org/10.1056/NEJMoa0707056
- Van Dolah FM, Ramsdell JS (1992). Okadaic acid inhibits a protein phosphatase activity involved in formation of the mitotic spindle of GH4 rat pituitary cells. J Cell Physiol, 152, 190-8. https://doi.org/10.1002/jcp.1041520124
- Vivanco I, Sawyers, CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501. https://doi.org/10.1038/nrc839
- Wang W, Abbruzzese JL, Evans DB, et al (1999). The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res, 5, 119-27.
- Wang XJ, Liu B, Li N, et al (2008). IPP5, a novel protein inhibitor of protein phosphatase 1, promotes G1/S progression in a thr-40-dependent manner. J Biol Chem, 283, 12076-84. https://doi.org/10.1074/jbc.M801571200
- Wang YY, Li L, Wei S, et al (2013). Human papillomavirus (HPV) infection in women participating in cervical cancer screening from 2006 to 2010 in Shenzhen City, South China. Asian Pac J Cancer Prev, 14, 7483-7. https://doi.org/10.7314/APJCP.2013.14.12.7483
- Woods CM, Zhu J, McQueney PA, et al (1995). Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med, 1, 506-26.
- Zanetta G, Fei F, Mangioni C (2000). Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol, 27, 23-7.
- Zeng QY, Huang Y, Zeng LJ, et al (2012). IPP5, a novel inhibitor of protein phosphatase 1, suppresses tumor growth and progression of cervical carcinoma cells by inducing G2/M arrest. Cancer Genetics, 205, 442-52. https://doi.org/10.1016/j.cancergen.2012.06.002
- Zeng QY, Huang Y, Zeng LJ, et al (2009). Effect of IPP5, a novel inhibitor of PP1, on apoptosis and the underlying mechanisms involved. Biotechnol. Appl Biochem, 54, 231-8. https://doi.org/10.1042/BA20090168